NEP inhibitors enhance C-type natriuretic peptide-induced relaxation in porcine isolated coronary artery

Antos, 2005, ATP-independent activation of natriuretic peptide receptors, J. Biol. Chem., 280, 26,928, 10.1074/jbc.M505648200 Barton, 1998, Endothelium-independent relaxation and hyperpolarization to C-type natriuretic peptide in porcine coronary arteries, J. Cardiovasc. Pharmacol., 31, 377, 10.1097/00005344-199803000-00008 Brandt, 1997, Neutral endopeptidase regulates C-type natriuretic peptide metabolism but does not potentiate its bioactivity in vivo, Hypertension, 30, 184, 10.1161/01.HYP.30.2.184 Casco, 2002, Natriuretic peptide system gene expression in human coronary arteries, J. Histochem. Cytochem., 50, 799, 10.1177/002215540205000606 Chauhan, 2003, Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor, Proc. Natl. Acad. Sci. U. S. A., 100, 1426, 10.1073/pnas.0336365100 Chauhan, 2004, C-type natriuretic peptide: new candidate for endothelium-derived hyperpolarising factor, Int. J. Biochem. Cell Biol., 36, 1878, 10.1016/j.biocel.2003.09.009 Chen, 1998, C-type natriuretic peptide: the endothelial component of the natriuretic peptide system, J. Cardiovasc. Pharmacol., 32, S22 Corti, 2001, Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?, Circulation, 104, 856, 10.1161/hc4001.097191 Ferro, 1998, Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo, Circulation, 97, 2323, 10.1161/01.CIR.97.23.2323 Gonzalez, 1998, Characterization of neutral endopeptidase in vascular cells, modulation of vasoactive peptide levels, Eur. J. Pharmacol., 345, 323, 10.1016/S0014-2999(98)00038-7 Graf, 1993, Degradation of bradykinin by neutral endopeptidase (EC 3.4.24.11) in cultured human endothelial cells, Eur. J. Clin. Chem. Clin. Biochem., 31, 267 Graf, 1995, Regulation and differential expression of neutral endopeptidase 24.11 in human endothelial cells, Hypertension, 26, 230, 10.1161/01.HYP.26.2.230 Graf, 1998, Glucocorticoids and protein kinase C regulate neutral endopeptidase 24.11 in human vascular smooth muscle cells, Basic Res. Cardiol., 93, 11, 10.1007/s003950050056 Honing, 2001, C-type natriuretic peptide-induced vasodilation is dependent on hyperpolarization in human forearm resistance vessels, Hypertension, 37, 1179, 10.1161/01.HYP.37.4.1179 Komatsu, 1992, Vascular natriuretic peptide, Lancet, 340, 622, 10.1016/0140-6736(92)92167-E Komatsu, 1996, Regulation of secretion and clearance of C-type natriuretic peptide in the interaction of vascular endothelial cells and smooth muscle cells, J. Hypertens., 14, 585, 10.1097/00004872-199605000-00007 Krassoi, 2000, Improvement by phosphoramidon of damaged endothelial function in porcine coronary artery, Ann. Thorac. Surg., 70, 878, 10.1016/S0003-4975(00)01632-5 Lapointe, 2002, Cardioprotective effects of vasopeptidase inhibitors, Can. J. Cardiol., 18, 415 Maguire, 1997, Endothelin converting enzyme (ECE) activity in human vascular smooth muscle, Br. J. Pharmacol., 122, 1647, 10.1038/sj.bjp.0701564 Maxwell, 1995, Effects of inhibiting neutral endopeptidase and kinase II on coronary and systemic hemodynamics in rats, Am. J. Physiol., 269, H1016 McDowell, 1997, The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides, Br. J. Clin. Pharmacol., 43, 329, 10.1046/j.1365-2125.1997.00545.x Morishige, 2000, Local adenovirus-mediated transfer of C-type natriuretic peptide suppresses vascular remodeling in porcine coronary arteries in vivo, J. Am. Coll. Cardiol., 35, 1040, 10.1016/S0735-1097(99)00625-7 Naruko, 1996, C-type natriuretic peptide in human coronary atherosclerotic lesions, Circulation, 94, 3103, 10.1161/01.CIR.94.12.3103 Pu, 2003, Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats, Am. J. Hypertens., 16, 931, 10.1016/S0895-7061(03)01029-X Schulz, 2005, C-type natriuretic peptide and guanylyl cyclase B receptor, Peptides, 26, 1024, 10.1016/j.peptides.2004.08.027 Skidgel, 1984, Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase, Peptides, 5, 769, 10.1016/0196-9781(84)90020-2 Soleilhac, 1992, A 94-kDa protein, identified as neutral endopeptidase-24.11, can inactivate atrial natriuretic peptide in the vascular endothelium, Mol. Pharmacol., 41, 609 Suga, 1992, Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of “vascular natriuretic peptide system”, J. Clin. Invest., 90, 1145, 10.1172/JCI115933 Vijayaraghavan, 1990, The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase), J. Biol. Chem., 265, 14150, 10.1016/S0021-9258(18)77280-3 Wang, 1994, Metabolism of substance P and neurokinin A by human vascular endothelium and smooth muscle, Peptides, 15, 497, 10.1016/0196-9781(94)90212-7 Wei, 1994, Vascular actions of C-type natriuretic peptide in isolated porcine coronary arteries and coronary vascular smooth muscle cells, Biochem. Biophys. Res. Commun., 205, 765, 10.1006/bbrc.1994.2731 Wiley, 2001, Physiological antagonism of endothelin-1 in human conductance and resistance coronary artery, Br. J. Pharmacol., 133, 568, 10.1038/sj.bjp.0704119 Wright, 1996, C-type natriuretic peptide-mediated coronary vasodilation: role of the coronary nitric oxide and particulate guanylate cyclase systems, J. Am. Coll. Cardiol., 28, 1031, 10.1016/S0735-1097(96)00241-0